-
B. Riley FBR: 3 Reasons To Buy Alimera Sciences
Friday, June 29, 2018 - 2:50pm | 431Read More...Nano-cap pharma company Alimera Sciences Inc (NASDAQ: ALIM) could nearly triple in value for three key reasons, according to B. Riley FBR. The Analyst Analyst Andrew D'Silva initiated coverage of Alimera Sciences with a Buy rating and $2.75 price target. The Thesis Alimera is a...
-
3 Medical Tech Trading Ideas With Upcoming Catalysts
Tuesday, September 29, 2015 - 9:34am | 560Read More...Caroline Corner, an analyst at Cantor Fitzgerald that covers medical technology highlighted three companies with upcoming catalysts. The three names are: Alimera Sciences Inc (NASDAQ: ALIM), Cerus Corporation (NASDAQ: CERS), and Intersect ENT Inc (NASDAQ: XENT). Corner stated all three...
-
Alimera Sciences Confirms ILUVIEN NDA Resubmission Has Been Accepted by the FDA
Wednesday, June 1, 2011 - 11:41am | 138Read More...Less than one hour before the close yesterday, Benzinga heard positive rumors that the NDA for ILUVIEN, which was resubmitted roughly two weeks ago, had been accepted by the Food and Drug Administration. The drug, which is a joint venture between pSivida (NASDAQ: PSDV) and Alimera Sciences (...
